Investigational drug · Phase 2
LTI-03
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis (IPF).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "LTI-03"
First trial start
2026
Feb 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LTI-03", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis (IPF)
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "LTI-03" as an intervention, largest first.
- A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisPivotal-lookingRecruiting
Rein TherapeuticsIndustry
NCT06968845 · 120 participants (planned) · Start Feb 2, 2026 · Primary completion Sep 30, 2027
Drug: LTI-03; Placebo · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Birmingham, Alabama; Los Angeles, California; San Diego, California · 48 sites in all
Rein TherapeuticsIndustry
NCT04233814 · 71 participants · Start Jan 20, 2020 · Primary completion Dec 23, 2021
Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03); Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Belfast, United Kingdom
Rein TherapeuticsIndustry
NCT05954988 · 24 participants · Start Jul 6, 2023 · Primary completion Sep 25, 2024
Drug: LTI-03; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Los Angeles, California; Giessen, Germany · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study.
Molyneaux PL, Hirani NA, Chia CCK, et al. · Nat Commun 2026
- Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study.
Molyneaux PL, Hirani NA, Chia CCK, et al. · medRxiv 2025
- LTI-03 peptide demonstrates anti-fibrotic activity in ex vivo lung slices from patients with IPF.
MacKenzie B, Mahavadi P, Pinho Jannini-Sa YA, et al. · iScience 2025
- Pre-clinical proof-of-concept of anti-fibrotic activity of caveolin-1 scaffolding domain peptide LTI-03 in ex vivo precision cut lung slices from patients with Idiopathic Pulmonary Fibrosis.
MacKenzie B, Mahavadi P, Jannini-Sa YAP, et al. · bioRxiv 2024
Also in development for Idiopathic Pulmonary Fibrosis (IPF)
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- DeupirfenidonePhase 32 trials
PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- INS018_055Phase 32 trials
InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- TDI01Phase 32 trials
Beijing Tide Pharmaceutical Co., Ltd · GVHD, Chronic, Idiopathic Pulmonary Fibrosis (IPF)
- AK3280Phase 31 trial
Shanghai Ark Biopharmaceutical Co., Ltd. · Idiopathic Pulmonary Fibrosis (IPF)
- HB0056Phase 22 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · Asthma, Idiopathic Pulmonary Fibrosis (IPF)
- AGMB-447Phase 21 trial
Agomab Spain S.L.U. · Idiopathic Pulmonary Fibrosis (IPF)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.